Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Konstantin Schlick, Florian Hohla, Frank Hamacher, Hubert Hackl, Clemens Hufnagl, Steiner Markus, Teresa Magnes, Simon Peter Gampenrieder, Thomas Melchardt, Stefan Stättner, Cornelia Hauser-Kronberger, Richard Greil, Gabriel Rinnerthaler
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Taylor & Francis Group 2021-02-01
Saila:	Future Science OA
Gaiak:	FOLFIRINOX gemcitabine miRNA pancreatic cancer
Sarrera elektronikoa:	https://www.future-science.com/doi/10.2144/fsoa-2020-0128
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!